Retatrutide · 8 min read
Retatrutide: A Complete Guide to the Trial Results and Timeline
What retatrutide is, what Lilly reported in the TRIUMPH trials, why it is not legally available, and when an FDA decision could come.
Read the story →TOPIC DESK · RETATRUTIDE
The next major obesity drug is still being studied.
Retatrutide is an investigational triple agonist from Eli Lilly. The trial numbers have drawn attention, but it is not FDA approved and cannot legally be compounded.
30.3%average weight loss at 104 weeks in TRIUMPH-1
2,339participants in the pivotal obesity trial
2027planned first quarter BLA filing
EXPLAINERS
Know what is real
Retatrutide · 7 min read
Retatrutide vs Zepbound: What the Trial Data Really Says
A careful comparison of retatrutide and Zepbound, including study results, approval status, and the limits of comparing separate trials.
Read the story →THE PATH AHEAD
When could it arrive?
July 23, 2026
Lilly announces its filing plan
The company said it plans to file a Biologics License Application in the first quarter of 2027.
First quarter 2027
Planned FDA submission
The review clock would begin after the agency accepts the application.
Late 2027 to mid 2028
Realistic approval range
Priority review could bring a decision in late 2027. Standard review math points roughly to January through March 2028.